We are live on ! Find out more

Innate Pharma

IPHA

Market cap $173M

1.55 USD

+0.04

2.65%

At close Updated Nov 10, 12:40 PM EST

1 day

2.65%

5 days

10.71%

1 month

4.73%

3 months

-30.18%

6 months

9.15%

Year to date

-14.84%

1 year

-32.61%

5 years

-71.35%

10 years

-74.38%

About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Employees: 163

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.7%

Neutral 77.3%

Negative 0%

Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript

Innate Pharma Q3 Earnings Call Highlights

Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the company outlined its third-quarter 2026 business update.

Innate Pharma Q3 Earnings Call Highlights

Innate Pharma Reports Third Quarter 2026 Business and Financial Update

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026. “As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We look forward to presenting Phase 1 dose-escalation data from IP.

Innate Pharma Reports Third Quarter 2026 Business and Financial Update

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclum.

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update.

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

Zacks Investment Research

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

Zacks Investment Research

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Zacks Investment Research

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™